Carvolix is develops innovative new-generation mini-invasive implants to restore essential physiological functions.
Carvolix has raised $9.3M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2024.
Carvolix's investors include Kreos Capital, Edwards Lifesciences.
Carvolix is headquartered in Paris, France.
Carvolix is develops innovative new-generation mini-invasive implants to restore essential physiological functions.
Carvolix is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Carvolix — Funding & Investors." VCBacked, July 15, 2024, https://www.vcbacked.co/company/carvolix. Accessed October 5, 2026.
VCBacked. (2024). Carvolix — Funding & Investors. Retrieved October 5, 2026, from https://www.vcbacked.co/company/carvolix
{{cite web |title=Carvolix — Funding & Investors |url=https://www.vcbacked.co/company/carvolix |website=VCBacked |access-date=October 5, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated